Arrowhead Research Corporation is a biopharmaceuticalcompany developing targeted RNAi therapeutics.
ARC-520 is an RNAi-based drug candidate that seeks to provide a functional cure for chronic HBV infection.
DPCs are non-lipid, targeted siRNA delivery vehicles that have shown deep and durable gene knockdown.
RNAi is a cellular process that Arrowhead is harnessing to produce therapeutic candidates that shut down disease-causing genes.
3:30 pm ET